Therapeutics News and Research

RSS

Pfizer, DxS sign agreement to develop a diagnostic test kit for CDX-110 to treat patients with GBM

Pfizer Inc. and DxS (a wholly owned subsidiary of QIAGEN N.V.) today announced that they have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110), an immunotherapy vaccine in development for the treatment of glioblastoma multiforme (GBM).

5 Feb 2010

TenX Biopharma acquires exclusive global rights to zanolimumab from Genmab

TenX Biopharma, Inc. announced today it has signed a licensing agreement to acquire exclusive worldwide rights to develop and commercialize zanolimumab (HuMax-CD4®) from Genmab A/S.

4 Feb 2010

Alkermes develops proprietary LinkeRx technology platform to create injectable antipsychotics

Alkermes, Inc. today announced that it has developed a novel, proprietary LinkeRx™ technology platform to enable the creation of injectable extended-release versions of antipsychotics and other central nervous system (CNS) therapies.

4 Feb 2010

BioMarin Pharmaceutical signs stock purchase agreement to acquire LEAD Therapeutics

BioMarin Pharmaceutical Inc. announced today that it has entered into a stock purchase agreement to acquire LEAD Therapeutics, Inc. (LEAD), a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of patients with rare, genetically defined cancers.

4 Feb 2010

CTD seeks small molecule drug discovery and therapeutic antibody targets from academic researchers

A major centre created by the Medical Research Council (MRC) and MRC Technology (MRCT) in order to fast-track the discovery and development of novel drugs, opens its first call for targets today.

4 Feb 2010

Akela announces the outcomes of two legal cases involving former employees

Akela a leader in the development of therapeutics for the treatment of pain and its wholly owned subsidiary, PharmaForm, a leader in the contract pharmaceutical development and manufacturing business, today announced the outcomes of two legal cases involving former employees.

4 Feb 2010

Type 1 diabetes: Regeneration exhibits potential as a possible cure

A hormone responsible for the body's stress response is also linked to the growth of insulin-producing cells in the pancreas, according to JDRF- funded researchers at the Salk Institute for Biological Studies in California. The findings are the latest advances to underscore the potential for regeneration as a key component of a possible cure for type 1 diabetes.

4 Feb 2010

PLX cell therapy may be an effective treatment for ischemic stroke disorder

Pluristem Therapeutics Inc. today announced that the results of a pre-clinical study in an animal model of ischemic stroke demonstrated that its PLacental eXpanded (PLX) cell therapy may be an effective treatment for this disorder.

4 Feb 2010

ACT and Brown Cancer Center scientist collaborate in discovery of new therapeutics for cancer

Advanced Cancer Therapeutics (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, today announced that it has signed an agreement to leverage the computational chemistry expertise of Dr. John Trent, Associate Professor, Department of Medicine at the University of Louisville’s James Graham Brown Cancer Center (Brown Cancer Center), to accelerate the identification of new clinical candidates for the prevention and treatment of cancer.

4 Feb 2010

Emerging Healthcare Solutions completes due diligence and review requirements with ThromboVision

Emerging Healthcare Solutions, Inc. announced today that the company has successfully completed the due diligence and review requirements under their recent option agreement with ThromboVision, a company that has licensed the patent on the new T-Guide® Platelet Function Analyzer, which is currently going through regulatory clearance review.

4 Feb 2010

Study: Generic nifedipine product not bioequivalent to Adalat XL

An extended release generic nifedipine product (Mylan-Nifedipine extended release 60 mg formerly Gen-Nifedipine extended release 60mg, Genpharm ULC) is not bioequivalent to the Canadian originator product, Adalat(R) XL(R), according to the results of a study recently published in the International Journal of Clinical Pharmacology and Therapeutics.

4 Feb 2010

Phase 2a clinical trial results of VX-809 in patients with CF announced

Vertex Pharmaceuticals Incorporated today announced results from a preliminary analysis of data from a 28-day Phase 2a clinical trial of VX-809 in patients with cystic fibrosis (CF) who are homozygous for the F508del mutation.

4 Feb 2010

AMPYRA for MS: Acorda Therapeutics announces wholesale pricing and patient assistance program

Acorda Therapeutics, Inc. today announced the wholesale acquisition cost (WAC) for AMPYRA™ (dalfampridine) Extended Release Tablets will be $1,056 per 30-day supply (60-count pill bottle), an annual cost of $12,850. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is expected to be available in March 2010.

3 Feb 2010

Maximizing quality in clinical trials is emphasized at community workshop

A community workshop sponsored by SNM's Clinical Trials Network (CTN) officially kicked off on Feb. 1, in Albuquerque, N.M., and presented participants with a series of educational sessions on the use of molecular imaging in clinical trials for investigational therapeutic drugs.

3 Feb 2010

MV vaccine prevents TB in people with HIV infection

Results from clinical trials conducted in Tanzania show that a new vaccine against tuberculosis, Mycobacterium vaccae (MV), is effective in preventing tuberculosis in people with HIV infection. Findings from the trials, which were conducted by investigators from Dartmouth Medical School in the United States, will be published in the next issue of AIDS, the leading journal in the field of HIV and AIDS research. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

3 Feb 2010

Repros Therapeutics receives FDA confirmation for initiating Androxal IND

Repros Therapeutics Inc. today announced that the Company has received verbal confirmation from the Division of Metabolic and Endocrine Drug Products of the Food and Drug Agency that the Company may initiate its Investigational New Drug Application for the study of oral Androxal® in the treatment of hypogonadal men with Type II Diabetes (T2D) with a Phase IIa trial.

3 Feb 2010

Compugen discovers CGEN-15001 protein for treatment of autoimmune disorders

Compugen Ltd. announced today the discovery and experimental validation of CGEN-15001 for the treatment of autoimmune disorders.

2 Feb 2010

Vantia Therapeutics initiates Phase IIb trial of VA106483 for nocturia

Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, today announces it has begun its planned Phase IIb trial of its lead development compound VA106483 for nocturia.

2 Feb 2010

Mentor Capital's Cancer Immunotherapy Index: First funding tranche to extend investment closes

Mentor Capital, Inc.'s first funding tranche to extend its investment in its proprietary Cancer Immunotherapy Index closes today. Cash investment from 1,400 existing shareholders projects to be approximately 20% oversubscribed from target. Company management reservation to fund will be correspondingly reduced to remain within the $1.2 Million seed funding limit. Already authorized follow-on public funding tranches total an additional $125 Million that will also be targeted for investment into the best of the Cancer Immunotherapy Index companies.

2 Feb 2010

New therapeutic made from tobacco plants shown to arrest West Nile virus infection

A new therapeutic made from tobacco plants has been shown to arrest West Nile virus infection, according to a new study by Arizona State University scientist Qiang Chen and his colleagues.

2 Feb 2010

Therapeutics News and Research

Pfizer, DxS sign agreement to develop a diagnostic test kit for CDX-110 to treat patients with GBM

TenX Biopharma acquires exclusive global rights to zanolimumab from Genmab

Alkermes develops proprietary LinkeRx technology platform to create injectable antipsychotics

BioMarin Pharmaceutical signs stock purchase agreement to acquire LEAD Therapeutics

CTD seeks small molecule drug discovery and therapeutic antibody targets from academic researchers

Akela announces the outcomes of two legal cases involving former employees

Type 1 diabetes: Regeneration exhibits potential as a possible cure

PLX cell therapy may be an effective treatment for ischemic stroke disorder

ACT and Brown Cancer Center scientist collaborate in discovery of new therapeutics for cancer

Emerging Healthcare Solutions completes due diligence and review requirements with ThromboVision

Study: Generic nifedipine product not bioequivalent to Adalat XL

Phase 2a clinical trial results of VX-809 in patients with CF announced

AMPYRA for MS: Acorda Therapeutics announces wholesale pricing and patient assistance program

Maximizing quality in clinical trials is emphasized at community workshop

MV vaccine prevents TB in people with HIV infection

Repros Therapeutics receives FDA confirmation for initiating Androxal IND

Compugen discovers CGEN-15001 protein for treatment of autoimmune disorders

Vantia Therapeutics initiates Phase IIb trial of VA106483 for nocturia

Mentor Capital's Cancer Immunotherapy Index: First funding tranche to extend investment closes

New therapeutic made from tobacco plants shown to arrest West Nile virus infection

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News